Availability of Transgene's 2024 Universal Registration Document (URD)

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers -- AMF) on April 10, 2025, under number D.25-0243.

This document, available on the AMF's website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene's website (www.transgene.fr)

It includes the following documents:

   -- the Annual Financial Report; 
 
   -- the Board of Directors' Corporate Governance Report; 
 
   -- the Statutory Auditors' Reports; 
 
   -- information on the Company's share capital, including the share buyback 
      program; 
 
   -- information on the Statutory Auditors' fees. 

The Universal Registration Document also includes information on the Company's Environmental, Social and Governance $(ESG)$ factors.

Attachment

   -- 20250410_Transgene_publication_URD_2024_EN 

(END) Dow Jones Newswires

April 10, 2025 14:15 ET (18:15 GMT)